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CT chestAbstract Background: Pulmonary air-space containing cavities signify major dissuade that hold
gas exchange functions back and bring about recurrent suppuration.
Purpose: The aim of this work is to evaluate the impact of percutaneous local inoculation of
focal benign cavitary lung lesions with synthetic material (gelfoam) guided with chest computed
tomography (CT) on the patient outcome based on clinical, laboratory, functional and radiological
parameters.
Patients and methods: A prospective simple randomized controlled trial was conducted on
twenty eight patients with focal benign cavitary lung lesion less than 10 cm in diameter in whom
surgical resection was contraindicated or refused. They were subdivided into two groups: group I
(medically treated): 14 patients were followed up for three months with medical prophylaxis with
quinolone plus clindamycin and group II (gelfoam inoculated): 14 patients percutaneous locally
injected with gelfoam under CT guidance for a single session.
Results: Gelfoam inoculated group (group II) presented more prevalence over medically treated
group (group I) in the reduction of the frequency of infective exacerbations (71.42%), absence of
leukocytosis (85.7%), functional improvement (42.85%), reduction of cavity size (57.14%) and
cavitary obliteration (35.71%). Both groups were matched regarding the absence of hemoptysis
and negative sputum cultures with high percentage (92.85%). However, reduction of the frequency
of hospitalization predominated in group I. Significant statistical differences were present in
radiological parameters only (reduction of size (0.042) and cavity obliteration (0.002). Success rate
of procedure in the studied group was (35.71%).
Conclusion: Percutaneous gelfoam injection may share in staged palliation and weeding out of
pulmonary cavitary lesions with simple noninvasive image guided procedure.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Cavities and cysts are commonly encountered lesions in the
lung on chest radiography and chest computed tomography
712 A.M. Abumossalam et al.CT. The differential diagnosis of such lesions is variable since
many different processes of acquired or congenital origin can
cause these abnormalities. Cysts and cavities are seen as foci
of decreased lung density with well defined walls [1,2]. In
contrast, emphysematous airspaces usually lack such percepti-
ble walls (bullae and blebs are exceptions) [3]. From the patho-
logical point of view a cavity has been defined in as a gas-filled
space within a zone of pulmonary consolidation or within a
mass or nodule, produced by the discharge of a necrotic part
of the lesion via the bronchial tree and radiographically as a
lucency within a zone of pulmonary consolidation, a mass,
or a nodule; hence, a lucent area within the lung may or
may not contain a fluid level and is surrounded by a wall,
usually of variable thickness [4]. Cavities larger than 6 cm in
diameter or if symptoms last more than 12 weeks with appro-
priate therapy, have little chances for only conservative heal-
ing, and surgical therapy should be well thought-out, if
general condition allows [5]. Surgical resection of lung cavity
is the treatment of choice for about 10% of patients. It is indi-
cated in ineffectively treated lung abscess more than 6 weeks,
suspicion on cancer and size more than 6 cm. Lobectomy is
the resection of choice for large or central position of abscess.
Atypical resection or segmentectomy are satisfactory
procedures, if it is possible to remove complete abscess and
if necessary surrounding lung tissue with necrotizing pneumo-
nia [6]. Results of surgical treatment depend mostly on the
general condition and immunity of patient. Mortality rate after
surgical resections is about 11–28% [7]. Minimal invasive
surgical procedures, such as video assisted thoracoscopy is a
method of choice for peripheral localization of lung abscess
without pleural adhesions and fibrothorax. Consequences of
this surgical procedure are satisfactory, but this intervention
requires general anesthesia, double lumen endotracheal tube
[8]. Overall mortality in lung abscess treatment is about
2.0–38.2% [9] with important roles of patient age, malnutri-
tion, comorbidity, immunity, appropriate antibiotics and
supportive therapy. The usage of intra-cavitary fibrinolytic
agents (streptokinase, urokinase) is not recommended, because
the possibility of bronchopulmonary or bronchopleural fistula
can occur [10].
Gelfoam sterile compressed sponge is a water-insoluble,
hemostatic device prepared from purified porcine skin gelatin,
and capable of absorbing up to 45 times its weight of whole
blood [11]. The absorptive capacity of gelfoam is a function
of its physical size, increasing as the size of the gelatin sponge
increases [12]. So our objective in this research was to evaluate
the impact of percutaneous local inoculation of focal benign
cavitary lung lesions with synthetic material (gelfoam) guided
with chest computed tomography on the patient outcome
based on clinical, laboratory, functional and radiological
parameters.
Patients and methods
A prospective simple randomized controlled trial was
conducted on twenty eight patients with focal benign cavitary
lung lesion in whom surgical resection was contraindicated or
refused. They were admitted in Chest Medicine Department
Mansoura University Hospitals during the period from
December 2014 to January 2016. They were subdivided into
two groups:Group I (medically treated group): 14 patients were
followed up for three months with medical prophylaxis in
the form of (levofloxacin 500 mg/day and clindamycin
300 mg twice/day for five days per month) [13].
Group II (gel inoculated group): 14 patients were percuta-
neous locally injected under CT guidance with gelfoam flux
for a single session.
The cases will be selected on a randomized basis according to
time of medical consultation one for group I and second for
group II. Patients signed their written consents after detailed
explanation of the study protocol. Local ethical approval had
been obtained; clinical, laboratory, functional and radiological
evaluation was conducted three months after the procedure.
Inclusion criteria:
The term cavity is used to refer to an air-containing lesion
with a relatively thick (>4 mm) wall or within an area of a
surrounding infiltrate or mass while cyst wall ranged from 2
to 4 mm in thickness [14].
Lung cavity less than 10 cm in diameter and >4 mm in wall
thickness or cyst <10 cm in diameter (2–4 mm wall) due to:
(1) Chronic lung cavity >3 months due to pyogenic or
fungal infections.
(2) Chronic tuberculous lung cavities after verification of
smear and culture negativity.
(3) Simple non infected lung cyst.
(4) Cavitary lung lesions due to (rheumatoid arthritis,
sarcoidosis or Wagner’s granulomatosis).
(5) Patient refused or contraindicated for surgery.
Exclusion criteria:
(1) Malignant lung cavity.
(2) Other pulmonary air-space containing cavities (emphy-
sematous bullae, blebs, localized pneumothorax and
pneumatocele).
(3) Huge cavity more than 10 cm in diameter.
(4) Cavity with fluid level.
(5) Presence of active infection proved by fever, suppuration
and leucocytosis.
The patients were evaluated with the following parameter
before and after the end of the three months following the
procedure.
Clinical parameter
(1) Reduction of the frequency of infective exacerbations
(purulent sputum >1 cup per day/fever/wheezes) less
than one per month.
(2) Reduction of the frequency of hospital admission less
than one visit in 3 month duration.
(3) Absence of hemoptysis.
Laboratory parameter
(1) Absence of leukocytosis white blood cell count
<11.000/cubic mm.
(2) Negative sputum culture (aerobic and anaerobic media
and BACTEC).
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Spirogram (improvement of FEV1 more than 5.26%; based on
the fact that both lungs contain 19 segments so every segments
equals 1/19 of the lung hence, the degree of improvement could
be equalized to retaining functioning segment that = (1/19)
* 100 = 5.26%) [15].
Radiological parameter
(1) By CT chest reduction in the size of the cavity.
(2) By CT chest obliteration of cavity.
The procedure was considered successful if all parameters
were fulfilled otherwise the procedure was categorized as failed
one.
Procedure
All patients in both groups received medical treatment for five
days before starting the study and the clinical, laboratory,
functional and radiological; chest computed tomography (CT
chest) were evaluated to ensure the absence of exacerbation
and identify the preliminary parameters.
In group II, gelfoam flux was prepared by opening two
ampoules (each ampoule contain gelfoam sponge with the fol-
lowing features (Curaspon; 80 * 50 * 10 mm EMOH Cura
Medical B.V.) and dividing them into small pieces under asep-
tic technique then were enclosed into 50 cm syringe barrel from
its lower end then closing the plunger on the gelfoam then con-
nect this syringe with another one containing 25 cm saline
0.9% by three way cannula then dissolving them by agitation
method. Patients in group II were examined by computed
tomography scan for the localization of the site for entry that
is identified on the surface of the skin by a mark then steriliza-
tion of the skin by betadine 5% followed by insertion of Chiba
needle with (15 cm length and 18 gauge to ensure injecting the
jelly material) that connected to three ways connector one
50 cm syringe for application of negative pressure and another
50 cm syringe that contain gelfoam flux as demonstrated in
Fig. 2. After negative suction, the connector was opened with
gentle pressure for the inoculation of the flux. Immediate chest
CT chest cuts were taken to assess immediate complication inFigure 1 Computed tomography of chest illustrates CT chest of a 5
hemi-thorax: (A) CT chest pre-procedure. (B) CT chest post-proced
3 months after procedure (gelfoam inoculation) in transverse sections.the form of pneumothorax, spillover or incorrect inoculation,
gel leakage and hemoptysis. Serial chest radiograph was taken
in the consecutive two days for late complications as pneu-
monitis and spill over inoculation. Three months later all
parameters were repeated for procedure evaluation in both
groups as Fig. 1.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 21. Qualitative data were presented as num-
ber and percentage. Quantitative data were presented for nor-
mality by Kolmogorov–Smirnov test. Normally distributed
data were presented as mean and standard deviation. Compar-
ison between groups was done using Chi-square test. Student’s
t-test was used to compare between two groups. P value <0.05
was considered significant.
Results
Table 1 offers knowledge about demographic data of the stud-
ied cases that were 21 male (21%) and 7 female (25%) with
median age 45 ± 13.05 in group I and 52 ± 14.23 in group
II. Group I included 11 cases pyogenic abscess, 2 cases post-
tuberculous cavities and one lung cyst; on the other hand 10
cases of pyogenic abscess and four cases due to tuberculosis
were enrolled in group II.
Table 2 shows that gelfoam inoculated group (group II)
presented more prevalence over medically treated group
(group I) in the reduction of the frequency of infective exacer-
bations (71.42%), absence of leukocytosis (85.7%), functional
improvement (42.85%), reduction of cavity size (57.14%) and
cavitary obliteration (35.71%). Both groups were matched
regarding the absence of hemoptysis and negative sputum cul-
tures with high percentage (92.85%). However, reduction of
the frequency of hospitalization predominated in group I. Sig-
nificant statistical differences were present in radiological
parameters only (reduction of size (0.042) and cavity oblitera-
tion (0.002). Success rate of procedure in the studied group was
35.71%.
Table 3 showed that the incidence of complications encoun-
tered in our research was 21.42%; one case developed local
suppuration one case reported pneumothorax and one case2 year old male with post-tuberculous cavitary lesion on the left
ure showing reduction of cavitary size with partial obliteration
Figure 2 Demonstration of instruments used in inoculation procedure of gelfoam into cavitary lung lesion; Chiba needle, two syringe
50 cm two sponge of gelfoam.
Table 1 Demographic data in studied medically treated group and gelfoam inoculated one and types of cavitary lesions included.
Group I medically treated
group 14 cases
Group II gelfoam inoculated
group 14 cases
Total
Number and percent Number and percent
Male 10 (71.42%) 11 (78.57%) 21 (75%)
Female 4 (28.57%) 3 (21.42%) 7 (25%)
Age (mean ± SD) 45 ± 13.05 52 ± 14.23
Type of cavitary lesion included
Chronic pyogenic lung abscess 11 (78.57%) 10 (71.42%) 21 (75%)
Post-tuberculous cavity 2 (14.28%) 4 (28.57%) 6 (21.42%)
Lung cyst 1 (7.14%) 0 1 (3.57%)
Table 2 Assessment of clinical, laboratory, functional and radiological parameters between medically treated group and gelfoam
inoculated one.
Group I medically treated group 14 cases Group II gel inoculated group 14 cases P
valueNumber and percent Number and percent
Reduction of frequency of infective
exacerbations
9 (64.28%) 10 (71.42%) 0.885
Reduction of frequency of hospitalizations 12 (85.7%) 11 (78.57%) 0.920
Absence of hemoptysis 13 (92.85%) 13 (92.85%) 0.241
Absence of Leukocytosis <11.000/cubic mm 11 (78.57%) 12 (85.7%) 0.083
Negative sputum cultures 13 (92.85%) 13 (92.85%) 0.241
Improvement in FEV1 (5.26%) 4 (28.57%) 6 (42.85%) 0.074
CT radiological reduction of cavity size 3 (21.42%) 8 (57.14%) 0.042
CT radiological obliteration of cavity 0 5 (35.71%) 0.002
(Successful procedure) – 5 (35.71%)
(Failed procedure) – 9 (64.28%)
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our study.
Discussion
Still interventional procedures with minimal invasive approach
make their way to more and more clinical appliance on aregular basis aiming to provide service for those with pul-
monary disability or with averse surgical longing. Yet to our
search no studies were conducted on the value of inoculating
fillers specially gelfoam in pulmonary air containing spaces
as cavitary lesions. But its physical inertia supported usage
in neurosurgical procedure in obliterating arteriovenous
malformation and as microsphere in embolotherapy as well
Table 3 Complications of the gelfoam inoculation in patients
of group II.
Complications of gelfoam inoculation Number and percent
Local suppuration 1 (7.14%)
Hemoptysis 0
Spill over of gel foam to other lobes 0
Pneumonitis 0
Fever 1 (7.14%)
Pneumothorax 1 (7.14%)
Death 0
Total 3 (21.42%)
Iatrogenic pneumodesis 715as application in lung transplantation and closure of
bronchopleural fistulae gave us confidence to attempt this
approach in our research.
In our work, in gelfoam inoculated group; reduction of the
frequency of infective exacerbations (71.42%), absence of
leukocytosis (85.7%), functional improvement (42.85%),
reduction of cavity size (57.14%) and cavitary obliteration
(35.71%) were dominant parameters. That may be attributed
to the inert non inflammatory effect of gelfoam sponge and
absorbing capacity with subsequent organization. Their nonin-
flammatory properties were affirmed with the study by Correll
et al. [16] that studied the histology of gelfoam sterile com-
pressed sponge when implanted in muscle and reported no sig-
nificant tissue reaction. Cavitary size reduction may be
assigned by capacity to be organized without surrounding
limitations by adjacent pulmonary scars. Both groups were
balanced regarding the absence of hemoptysis and negative
sputum cultures with high percentage (92.85%) that over-
weighed their value clinically making no predilection. The total
success rate of procedure was (35.71%) in the studied cases.
There had been reports of fever associated with the use of
gelfoam, without demonstrable infection. Gelfoam sterile
compressed sponge may form a nidus of infection and abscess
formation [17], and had been reported to potentiate bacterial
growth. Giant-cell granuloma has been reported at the implan-
tation site of absorbable gelatin product in the brain [18], and
compression of the brain and spinal cord resulting from an
accumulation of sterile fluid. Foreign body reactions,
‘‘encapsulation” of fluid and hematoma had also been reported
following the use of absorbable gelatin sponge in closed space
[19]. Gelfoam had been applied locally in the lung in the study
by Nori and Pugkhem that conducted Intraoperative
brachytherapy using gelfoam radioactive plaque implants for
resected stage III non-small cell lung cancer with positive
margin [20]. In addition, gelfoam was used to control bleeding
from oozing surfaces in lung transplantation [21] and in
bronchoscopic management of bronchopleural fistulae [22].
Frequency of complications encountered in our research was
only in three cases 21.42%; one case developed local suppura-
tion, one case developed fever and case reported pneumotho-
rax without cases of mortality. They were well managed
without consequences.
Actually in our work there were many impediments and
limitations presented in the following, first small number of
cases that fulfilled the inclusion criteria. Second, previous
literature knowledge that gelfoam could be absorbed into body
tissues that made more suspicion about total absorption into
pulmonary cavity, however, safety of this synthetic materialmore than other fillers used in plastic surgery promoted us
to proceed in inoculating gelfoam keeping in our consideration
conducting other material under more future interventional
approach. Third, possibility of spontaneous resolution of these
cavitary lesions made some limitations in considering the
reduction of the cavity size as a good radiological parameter.
Lastly studying huge cavities was hardly enough to inoculate
large amount of this material for the fear of unanticipated
complications that may endanger the patient life.
Conclusions
Pulmonary cavitary gelfoam inoculation still stands a few steps
behind a promising success as a palliative minimal invasive
modality. Its modest achievement presumes a favorable pros-
perity with some modifications in material used and lesion
selection. More research on this material and its correlates
needs to be carried out for better evaluation and secure
application.Conflict of interests
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